1. Home
  2. SYRE vs NMFC Comparison

SYRE vs NMFC Comparison

Compare SYRE & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYRE
  • NMFC
  • Stock Information
  • Founded
  • SYRE 2013
  • NMFC 2010
  • Country
  • SYRE United States
  • NMFC United States
  • Employees
  • SYRE N/A
  • NMFC N/A
  • Industry
  • SYRE Biotechnology: Pharmaceutical Preparations
  • NMFC Finance/Investors Services
  • Sector
  • SYRE Health Care
  • NMFC Finance
  • Exchange
  • SYRE Nasdaq
  • NMFC Nasdaq
  • Market Cap
  • SYRE 1.1B
  • NMFC 1.2B
  • IPO Year
  • SYRE 2016
  • NMFC 2011
  • Fundamental
  • Price
  • SYRE $16.26
  • NMFC $10.42
  • Analyst Decision
  • SYRE Buy
  • NMFC Hold
  • Analyst Count
  • SYRE 5
  • NMFC 3
  • Target Price
  • SYRE $55.00
  • NMFC $11.00
  • AVG Volume (30 Days)
  • SYRE 545.5K
  • NMFC 332.8K
  • Earning Date
  • SYRE 08-06-2025
  • NMFC 08-04-2025
  • Dividend Yield
  • SYRE N/A
  • NMFC 12.57%
  • EPS Growth
  • SYRE N/A
  • NMFC N/A
  • EPS
  • SYRE N/A
  • NMFC 0.99
  • Revenue
  • SYRE N/A
  • NMFC $366,773,000.00
  • Revenue This Year
  • SYRE N/A
  • NMFC N/A
  • Revenue Next Year
  • SYRE N/A
  • NMFC N/A
  • P/E Ratio
  • SYRE N/A
  • NMFC $10.54
  • Revenue Growth
  • SYRE N/A
  • NMFC N/A
  • 52 Week Low
  • SYRE $10.91
  • NMFC $8.84
  • 52 Week High
  • SYRE $40.26
  • NMFC $12.55
  • Technical
  • Relative Strength Index (RSI)
  • SYRE 48.34
  • NMFC 40.63
  • Support Level
  • SYRE $16.43
  • NMFC $10.46
  • Resistance Level
  • SYRE $17.70
  • NMFC $10.67
  • Average True Range (ATR)
  • SYRE 0.99
  • NMFC 0.15
  • MACD
  • SYRE -0.02
  • NMFC -0.03
  • Stochastic Oscillator
  • SYRE 37.17
  • NMFC 16.52

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

Share on Social Networks: